Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Larazotide acetate reduces symptoms in celiac patients undergoing a gluten challenge

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines larazotide acetate in patients with celiac disease undergoing a gluten challenge.

News image

Celiac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten-free diet, which is difficult for many patients.

Larazotide acetate is a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae.
 
Dr Kelly and colleagues from Massachussetts, USA evaluated the efficacy and tolerability of larazotide acetate during gluten challenge.
 
The research team performed an exploratory, double-blind, randomized, placebo-controlled study including 184 patients who maintained a gluten-free diet before and during the study.

After a gluten-free diet run-in, patients were randomized to larazotide acetate or placebo, and received 2.7 grams of gluten daily for 6 weeks.

Larazotide acetate 1-mg limited gluten-induced symptoms
Alimentary Pharmacology & Therapeutics

The researchers' outcomes included an experimental biomarker of intestinal permeability, the lactulose-to-mannitol ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale, and anti-transglutaminase antibody levels.
 
The research team observed no significant differences in lactulose-to-mannitol ratios between larazotide acetate and placebo groups.

Larazotide acetate 1-mg limited gluten-induced symptoms measured by Gastrointestinal Symptom Rating Scale.

Mean ratio of anti-tissue transglutaminase IgA levels over baseline was 19 in the placebo group compared with 6, 4 and 8 in the larazotide acetate 1-, 4-, and 8-mg groups, respectively.

The team found that the adverse event rates were similar between larazotide acetate and placebo groups.
 
Dr Kelly and colleagues commented, "Larazotide acetate reduced gluten-induced immune reactivity and symptoms in patients with celiac disease undergoing gluten challenge and was generally well tolerated."

"However, no significant difference in lactulose-to-mannitol ratios between larazotide acetate and placebo was observed."

"Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with celiac disease."

Aliment Pharmacol Ther 2012: DOI: 10.1111/apt.12147
28 November 2012

Go to top of page Email this page Email this page to a colleague

 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us